Regression analyses of prognostic factors in metastatic malignant melanoma

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

“…While pretreatment serum LDH levels are prognostic factors for patients with metastatic melanoma, serum LDH levels can indicate the tumour response to vemurafenib in patients with metastatic melanoma [26,39,41]. We found no significant differences in LDH decrease upon treatment to vemurafenib, pointing towards a similar tumour biology and thus a similar initial response to selective BRAFi in the two groups.…”

“…To analyse the possible difference in tumour biology between the two groups we compared changes of LDH upon treatment with vemurafenib. LDH has been identified as a prognostic factor and is thought to correlate with tumour metabolism [26,[39][40][41]. In both groups we found a normalisation of the mean LDH upon vemurafenib treatment (mean serum LDH at week 8 was 203 U/L in the group treated beyond progression versus 207 U/L in the control group, p = 0.453) indicating no differences in the changes of tumour metabolism upon treatment (Fig.…”

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

“…While pretreatment serum LDH levels are prognostic factors for patients with metastatic melanoma, serum LDH levels can indicate the tumour response to vemurafenib in patients with metastatic melanoma [26,39,41]. We found no significant differences in LDH decrease upon treatment to vemurafenib, pointing towards a similar tumour biology and thus a similar initial response to selective BRAFi in the two groups.…”

“…To analyse the possible difference in tumour biology between the two groups we compared changes of LDH upon treatment with vemurafenib. LDH has been identified as a prognostic factor and is thought to correlate with tumour metabolism [26,[39][40][41]. In both groups we found a normalisation of the mean LDH upon vemurafenib treatment (mean serum LDH at week 8 was 203 U/L in the group treated beyond progression versus 207 U/L in the control group, p = 0.453) indicating no differences in the changes of tumour metabolism upon treatment (Fig.…”

Serological markers for melanoma

“…Several studies have reported on serum LDH levels as an independent prognostic factor in patients with stage IV disease. 10,14–18 Elevated serum LDH levels are assumed to reflect tumour cell turnover and tumour burden and have been shown to be of prognostic significance in other neoplastic disorders. 19 Elevated LDH levels are also observed in several conditions of tissue damage, such as myocardial infarction or haemolysis.…”

Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma

“…At the time of the analysis, to our knowledge, only a limited number of studies had focused on the prognostic value of the ESR level in cutaneous melanoma patients (10,11). In the Norwegian Radium Hospital, 177 metastatic melanoma patients treated with various chemotherapy regimens were included in a regression analysis of prognostic factors (10).…”

“…In the Norwegian Radium Hospital, 177 metastatic melanoma patients treated with various chemotherapy regimens were included in a regression analysis of prognostic factors (10). Multivariate analysis identified ESR >15 mm/h as a significant prognostic factor indicating short survival with a low probability of surviving for 3 months, whereas patients with normal ESR values had a median survival of 11.5 months, with 94% surviving for 3 months.…”

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

“…While pretreatment serum LDH levels are prognostic factors for patients with metastatic melanoma, serum LDH levels can indicate the tumour response to vemurafenib in patients with metastatic melanoma [26,39,41]. We found no significant differences in LDH decrease upon treatment to vemurafenib, pointing towards a similar tumour biology and thus a similar initial response to selective BRAFi in the two groups.…”

“…To analyse the possible difference in tumour biology between the two groups we compared changes of LDH upon treatment with vemurafenib. LDH has been identified as a prognostic factor and is thought to correlate with tumour metabolism [26,[39][40][41]. In both groups we found a normalisation of the mean LDH upon vemurafenib treatment (mean serum LDH at week 8 was 203 U/L in the group treated beyond progression versus 207 U/L in the control group, p = 0.453) indicating no differences in the changes of tumour metabolism upon treatment (Fig.…”

Serological markers for melanoma

“…Several studies have reported on serum LDH levels as an independent prognostic factor in patients with stage IV disease. 10,14–18 Elevated serum LDH levels are assumed to reflect tumour cell turnover and tumour burden and have been shown to be of prognostic significance in other neoplastic disorders. 19 Elevated LDH levels are also observed in several conditions of tissue damage, such as myocardial infarction or haemolysis.…”

Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma

“…At the time of the analysis, to our knowledge, only a limited number of studies had focused on the prognostic value of the ESR level in cutaneous melanoma patients (10,11). In the Norwegian Radium Hospital, 177 metastatic melanoma patients treated with various chemotherapy regimens were included in a regression analysis of prognostic factors (10).…”

“…In the Norwegian Radium Hospital, 177 metastatic melanoma patients treated with various chemotherapy regimens were included in a regression analysis of prognostic factors (10). Multivariate analysis identified ESR >15 mm/h as a significant prognostic factor indicating short survival with a low probability of surviving for 3 months, whereas patients with normal ESR values had a median survival of 11.5 months, with 94% surviving for 3 months.…”

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

“…While pretreatment serum LDH levels are prognostic factors for patients with metastatic melanoma, serum LDH levels can indicate the tumour response to vemurafenib in patients with metastatic melanoma [26,39,41]. We found no significant differences in LDH decrease upon treatment to vemurafenib, pointing towards a similar tumour biology and thus a similar initial response to selective BRAFi in the two groups.…”

“…To analyse the possible difference in tumour biology between the two groups we compared changes of LDH upon treatment with vemurafenib. LDH has been identified as a prognostic factor and is thought to correlate with tumour metabolism [26,[39][40][41]. In both groups we found a normalisation of the mean LDH upon vemurafenib treatment (mean serum LDH at week 8 was 203 U/L in the group treated beyond progression versus 207 U/L in the control group, p = 0.453) indicating no differences in the changes of tumour metabolism upon treatment (Fig.…”

Serological markers for melanoma

“…Several studies have reported on serum LDH levels as an independent prognostic factor in patients with stage IV disease. 10,14–18 Elevated serum LDH levels are assumed to reflect tumour cell turnover and tumour burden and have been shown to be of prognostic significance in other neoplastic disorders. 19 Elevated LDH levels are also observed in several conditions of tissue damage, such as myocardial infarction or haemolysis.…”

Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma

“…At the time of the analysis, to our knowledge, only a limited number of studies had focused on the prognostic value of the ESR level in cutaneous melanoma patients (10,11). In the Norwegian Radium Hospital, 177 metastatic melanoma patients treated with various chemotherapy regimens were included in a regression analysis of prognostic factors (10).…”

“…In the Norwegian Radium Hospital, 177 metastatic melanoma patients treated with various chemotherapy regimens were included in a regression analysis of prognostic factors (10). Multivariate analysis identified ESR >15 mm/h as a significant prognostic factor indicating short survival with a low probability of surviving for 3 months, whereas patients with normal ESR values had a median survival of 11.5 months, with 94% surviving for 3 months.…”